Recent news at the Food and Drug Administration (FDA) – including the deaths of patients allegedly linked to a Duchenne muscular dystrophy (DMD) drug, ousters of senior regulatory officials, and new, mercurial leadership initiatives – has made the health care industry (and hopefully the regulators themselves) take notice of the agency’s drug approval process. The FDA’s accelerated approval program seems to connect much of this news through its role in bringing the DMD to market in the first place, and the philosophical positions that leadership has taken on the program. To better understand this, let’s start with some background. 

The FDA created the Accelerated Approval Program in 1992 in response to the HIV/AIDS epidemic, when patient advocates demanded quicker access to promising, yet unproven, treatments for life-threatening conditions. Unlike traditional FDA approvals that require clear, pre-market evidence of improved survival or symptom relief, accelerated approval was designed to allow earlier approval of drugs that treat serious or life-threatening illnesses based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit.  In exchange, drug sponsors must conduct post-marketing confirmatory trials to verify the anticipated clinical benefit. If these trials fail to confirm the benefit, the FDA has the authority to withdraw the drug from the market. 

The pathway was codified by the 2012 Food and Drug Administration Safety and Innovation Act, expanding its scope to include drugs for serious conditions beyond HIV/AIDS, such as cancer, rare diseases, and genetic disorders. Since its inception, the program has played a central role in bringing critical therapies to the market, especially in rare diseases and oncology. 

Sarepta Therapeutics’ gene therapy for DMD has become a prominently debated example of both the promises and the pitfalls of accelerated approval. While a welcome treatment for this rare and deadly disease, the DMD gene therapy also has a complicated history. And although the FDA ultimately granted accelerated approval for ambulatory patients (before expanding the label later), it has long been treated with suspicion because of the close vote of the FDA advisory committee, uninspiring clinical outcome data, and the role that a prior Center for Biologics Evaluation and Research (CBER) director had in bringing it to market. Then, between March and July 2025, three patients died of acute liver failure while taking this DMD drug as well as a similar drug with the same platform. These serious adverse events raised alarm bells at the FDA, which swiftly requested that Sarepta halt drug distribution across all patient groups and place full clinical holds on its programs.  

Initially, Sarepta pushed back, arguing that the safety signals were confined to the (generally older) expanded, non-ambulatory patient population and that there was no evidence of similar risks among the (generally younger) ambulatory children with DMD. Sarepta refused the FDA’s request to halt distribution, citing the urgent unmet need for the drug and patient outcry. After its initial defiance, however, the company announced a voluntary pause in all U.S. shipments to implement updated safety labeling and preserve its working relationship with the FDA. While these moves de-escalated the standoff, the entire episode underscores the tension at the heart of accelerated approval: the desire for rapid access to innovation colliding with the need for robust safety oversight and clinical validation. 

This incident was followed closely by the sudden departure of the chief regulator for these types of therapies. Though more information is coming out about the nature of the CBER director’s leaving, the timing and circumstances correspond with the DMD episode and a resurfacing of his past preference for clearer safety and efficacy signals – an oft-cited issue with accelerated approvals – before approving drugs. His vocal criticism of the FDA’s use of surrogate endpoints and concern over the evidence base for rare‑disease and oncology drugs clashed with the agency’s accelerated approval momentum. The whiplash of the safety evaluation, shipment pause, reversal, and ultimate CBER departure could paint a very concerning future for pharmaceutical development. The industry prioritizes stability and predictability, and it seems that neither has been achieved over these past few weeks. 

Finally, as I wrote about several weeks ago, the FDA unveiled a new initiative known as the Commissioner’s National Priority Voucher Program, designed to accelerate the review of drugs that serve U.S. national interests. While more information must be provided on this program, it appears to further represent momentum behind the accelerated approval program, and drugs under this pathway should remain subject to the strict scrutiny that has made the FDA the gold standard it is today. 

Ultimately, accelerated approval remains a powerful tool, but one that must be wielded with scientific rigor and public trust. These episodes reveal both the strengths of the accelerated approval framework – such as its ability to bring drugs for rare diseases quickly to market – and its limitations – including the difficulty of confirming clinical efficacy – and they may prompt further reforms to strengthen the program’s safeguards. Congress already expanded the FDA’s authority in 2022 to ensure confirmatory trials are underway at the time of accelerated approval. New changes may follow, but recent news cycles are a reminder that early access is only as valuable as the evidence that follows, and that when hope meets risk, the balance must be carefully managed.